This has fuelled a continuous search for broad-spectrum topical non-antibiotic anti-biofilm therapies. For recalcitrant patients, antibiotics often alleviate symptoms in acute exacerbations but fail to eradicate the biofilm nidus which periodically sheds planktonic organisms resulting in a relapsing and remitting course of disease ( Foreman et al., 2011). The management of recalcitrant chronic rhinosinusitis (CRS) is increasingly challenged by difficult-to-treat polymicrobial biofilms and multidrug resistant bacteria which antibiotics often cannot effectively eradicate. Further studies including more patients and looking at longer treatment or improving the tonicity of the solution for better tolerability should be explored. Whilst not statistically significant, both groups showed similar improvement in symptoms and endoscopic scores.Ĭonclusion: This study concludes that twice daily CS (0.015 mg/mL) sinonasal rinses for 10 days is safe but not superior to culture-directed oral antibiotics. CS patients had 1/11 (9.09%) negative cultures, compared to 2/11 (18.18%) in the control group upon completion of the study. Results: CS demonstrated good safety profile with no major adverse events, no changes in UPSIT and transient serum silver level changes in 4 patients. Efficacy was assessed comparing microbiology results, Lund Kennedy Scores (LKS) and symptom scores using Visual Analog Scale (VAS) and Sino-Nasal Outcome Test (SNOT-22). Safety observations included pre- and post-treatment serum silver levels, University of Pennsylvania Smell Identification Test (UPSIT) and adverse event (AE) reporting. Patients were allocated to 10–14 days of culture directed oral antibiotics with twice daily saline rinses ( n = 11) or 10 days of twice daily 0.015 mg/mL CS rinses ( n = 11). Methods: Patients were included when they had previously undergone endoscopic sinus surgery and presented with signs and symptoms of sinus infection with positive bacterial cultures. This is the first study looking at the safety and efficacy of CS in recalcitrant CRS. However, due to the lack of scientific efficacy, it is only currently used as an alternative medicine. Colloidal silver (CS) has significant antibiofilm activity in vitro and in vivo against S. This has led to the search for broad-spectrum non-antibiotic antimicrobial therapies. 3Facultad Mexicana de Medicina Universidad La Salle, Department of Otolaryngology Head and Neck Surgery, Spanish Hospital of Mexico, Granada, Mexicoīackground: The management of recalcitrant chronic rhinosinusitis (CRS) is challenged by difficult-to-treat polymicrobial biofilms and multidrug resistant bacteria.2Adelaide Biofilm Test Facility, Sansom Institute for Health Research, University of South Australia, Adelaide, SA, Australia.
1Department of Surgery-Otolaryngology, Head and Neck Surgery, Basil Hetzel Institute for Translational Health Research, The University of Adelaide, Adelaide, SA, Australia.Ooi 1, Katharina Richter 1,2, Catherine Bennett 1, Luis Macias-Valle 1,3, Sarah Vreugde 1, Alkis J. FTC, FDA warn companies making coronavirus claims.In vitro intestinal toxicity of commercially available spray disinfectant products advertised to contain colloidal silver. In: Cummings Otolaryngology: Head & Neck Surgery. Chronic rhinosinusitis: Evidence-based medical treatment. Chronic poisoning: Trace metals and others. National Center for Complementary and Integrative Health. Drug products containing colloidal silver ingredients or silver salts offered over-the-counter (OTC) for the treatment and/or prevention of disease.
0 kommentar(er)
